Disease-modifying antirheumatic drug action (DMARD action)

“Disease-modifying antirheumatic drug action" refers collectively to the diverse mechanisms by which disease-modifying antirheumatic drugs suppress pathological immune responses in autoimmune diseases like rheumatoid arthritis. These actions include inhibition of lymphocyte proliferation and activation, suppression of pro-inflammatory cytokines production/signaling pathways, interference with antigen presentation/costimulation among immune cells, and direct effects on other cell types involved in joint inflammation and destruction. This term does not denote a single molecular entity but encompasses multiple pharmacological strategies aimed at altering disease progression rather than merely alleviating symptoms.

Other names

DMARD mechanismDisease modification in rheumatologyAntirheumatic immunosuppression

Varies by drug; includes: - Inhibition of dihydrofolate reductase and DNA synthesis (methotrexate) - Modulation/inhibition of immune cell function and proliferation (T cells, B cells, monocytes) - Blockade of cytokine signaling pathways including TNF and interleukins - Interference with antigen presentation or costimulatory signals between immune cells (abatacept)